Literature DB >> 14656459

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice.

Lisset Hermida1, Rayner Rodríguez, Laura Lazo, Ricardo Silva, Aída Zulueta, Glay Chinea, Carlos López, María G Guzmán, Gerardo Guillén.   

Abstract

A gene fragment encoding for the amino acids (aa) 286-426 from the dengue Envelope (E) protein was expressed in Escherichia coli as two forms of fusion proteins. In one case, the E fragment was fused to the first 45 aa of the P64k protein from Neisseria meningitidis (PD2) while, in the other, it was inserted within the lipoil-binding domain of the aforementioned bacterial protein (PD3). PD2 was obtained as insoluble form within the cytoplasm of the bacteria while PD3 was distributed equally as soluble and insoluble forms. The insoluble forms of each protein as well as the soluble fraction of PD3 were semipurified to test the antigenicity and the immunogenicity in mice. The forms containing the entire P64k protein exhibited the highest recognition with different polyclonal and monoclonal antibodies. Consequently, the neutralizing antibodies elicited by the recombinant proteins were higher in the case of PD3 forms than with PD2, independently of the solubility status. In addition, mice inoculated with the semipurified insoluble form of PD3 were partially protected against lethal challenge with dengue-2 virus, administered by intracerebral inoculation. The results suggested the folding and carrier capacity of the P64k protein over the E fragment, converting PD3 as an attractive vaccine candidate against dengue-2 virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14656459     DOI: 10.1016/j.jviromet.2003.09.024

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  11 in total

1.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

2.  The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

Authors:  Iris Valdés; Lázaro Gil; Yaremis Romero; Jorge Castro; Pedro Puente; Laura Lazo; Ernesto Marcos; María G Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

3.  DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.

Authors:  Jazmín García-Machorro; Moisés López-González; Olivia Barrios-Rojas; Cynthia Fernández-Pomares; Claudia Sandoval-Montes; Leopoldo Santos-Argumedo; Nicolás Villegas-Sepúlveda; Benito Gutiérrez-Castañeda; Leticia Cedillo-Barrón
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

4.  Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein.

Authors:  Iris Valdés; Lisset Hermida; Aída Zulueta; Jorge Martín; Ricardo Silva; Mayling Alvarez; María G Guzmán; Gerardo Guillén
Journal:  Mol Biotechnol       Date:  2007-01       Impact factor: 2.695

5.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

Review 6.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

7.  Next-generation dengue vaccines: novel strategies currently under development.

Authors:  Anna P Durbin; Stephen S Whitehead
Journal:  Viruses       Date:  2011-09-26       Impact factor: 5.048

8.  Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.

Authors:  Samantha Brandler; Marianne Lucas-Hourani; Arnaud Moris; Marie-Pascale Frenkiel; Chantal Combredet; Michèle Février; Hugues Bedouelle; Olivier Schwartz; Philippe Desprès; Frédéric Tangy
Journal:  PLoS Negl Trop Dis       Date:  2007-12-12

Review 9.  Dengue Fever: Causes, Complications, and Vaccine Strategies.

Authors:  Niyati Khetarpal; Ira Khanna
Journal:  J Immunol Res       Date:  2016-07-20       Impact factor: 4.818

Review 10.  Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

Authors:  Lucas Wilken; Guus F Rimmelzwaan
Journal:  Pathogens       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.